Find our latest news and company updates. For all media inquiries, contact us at communications@sonicincytes.com.
Sonic Incytes was recognized as a “Company to Watch” at the 25th Annual LSBC Awards Gala, presented by Farris. This...
Velacur™️ ACE Outperforms FibroScan®️ CAP for Liver Fat Quantification We are excited to announce that clinical data from Sonic Incytes’...
Sonic Incytes is pleased to announce they have received Food and Drug Administration (FDA) clearance for new Organ Guide and...
Sonic Incytes Medical Corp. is pleased to announce its project was selected for investment by the inaugural INOVAIT Focus Fund....
Sonic Incytes Medical Corp. is pleased to announce clinical data from a prospective multi-center study comparing the effectiveness of Velacur™️...
Sonic Incytes Medical Corp. is pleased to announce the inclusion of Velacur™️ — the first handheld 3D liver health assessment tool—in...
The poster entitled “Accuracy of Velacur™️ AI Powered Liver Guide in Identification of Liver” presented at the Digestive Disease Week...
Metabolic syndrome is a cluster of conditions that increase the risk of many chronic illnesses such as heart disease, stroke,...
Sonic Incytes Medical Corp. is pleased to host a live educational webinar on Novel Tools for Managing Metabolic Syndrome. Metabolic...
Following the closing of its US$7.3M Series A raise in December 2021, the Sonic Incytes Medical Corp. Board of Directors...